Herbal Psychopharmacology

Abstract

Dr. Jefferson is Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, and Distinguished Senior Scientist, Madison Institute of Medicine, Inc., 7617 Mineral Point Road, Suite 300, Madison, WI 53717, E-mail: [email protected]. Dr. Jefferson has disclosed that he was the recipient of grant/research support from Janssen, Organon, and Roche, is/was the recipient of grant/research support from Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, Eli Lilly, Novartis, Pfizer, Solvay, and Wyeth; is a consultant to GlaxoSmithKline; was a member of the speakers bureau for Abbott Labs, AstraZeneca, Forest Pharmaceuticals, and Pfizer; is/was a member of the speakers bureau for Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Wyeth; is a stock shareholder in Bristol-Myers Squibb, GlaxoSmithKline, and SciClone; and is a principal of Healthcare Technology Systems, Inc. The author also has disclosed none of the herbal products discussed in this article has been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity.